Trinity Biotech Company Insiders
TRIB Stock | USD 0.82 0.03 3.53% |
Trinity Biotech employs about 380 people. The company is managed by 15 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 25.33 employees per reported executive. Analysis of Trinity Biotech's management performance can provide insight into the company performance.
Ronan OCaoimh Chairman Executive Chairman of the Board |
Trinity |
Trinity Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.0819) % which means that it has lost $0.0819 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.95, whereas Return On Tangible Assets are projected to grow to (0.48). At present, Trinity Biotech's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 69.5 M, whereas Total Assets are forecasted to decline to about 64.9 M.The current year's Common Stock Shares Outstanding is expected to grow to about 184.9 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 826.9 K
Trinity Biotech Workforce Comparison
Trinity Biotech plc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 10,119. Trinity Biotech holds roughly 380 in number of employees claiming about 4% of equities under Health Care industry.
Trinity Biotech Profit Margins
The company has Profit Margin (PM) of (0.34) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.33 | 0.31 |
|
|
Trinity Biotech plc Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Trinity Biotech plc Price Series Summation is a cross summation of Trinity Biotech price series and its benchmark/peer.
Trinity Biotech Notable Stakeholders
A Trinity Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Trinity Biotech often face trade-offs trying to please all of them. Trinity Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Trinity Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John Gillard | CEO, President | Profile | |
Ronan OCaoimh | Executive Chairman of the Board | Profile | |
Louise Tallon | CFO Officer | Profile | |
Ronan ACA | Director Founder | Profile | |
James Walsh | Executive Director and Member of Compensation Committee | Profile | |
Jacqueline ONeill | Director Operations | Profile | |
Simon Dunne | Chief Officer | Profile | |
Fernando Devia | Ex Sales | Profile | |
Eibhlin Kelly | Chief Officer | Profile | |
Aris Kekedjian | CEO Chairman | Profile | |
Gary Keating | Chief Officer | Profile | |
Adrian Donohue | Chief Officer | Profile | |
Sanjiv Suri | VP America | Profile | |
Des Fitzgerald | Interim Officer | Profile | |
Colm Molloy | Group Culture | Profile |
About Trinity Biotech Management Performance
The success or failure of an entity such as Trinity Biotech plc often depends on how effective the management is. Trinity Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Trinity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Trinity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.50) | (0.48) | |
Return On Capital Employed | (0.55) | (0.52) | |
Return On Assets | (0.36) | (0.35) | |
Return On Equity | 0.90 | 0.95 |
Please note, the presentation of Trinity Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Trinity Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Trinity Biotech's management manipulating its earnings.
Trinity Biotech Workforce Analysis
Traditionally, organizations such as Trinity Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Trinity Biotech within its industry.Trinity Biotech Manpower Efficiency
Return on Trinity Biotech Manpower
Revenue Per Employee | 149.6K | |
Revenue Per Executive | 3.8M | |
Net Loss Per Employee | 63.2K | |
Net Loss Per Executive | 1.6M | |
Working Capital Per Employee | 63.2K | |
Working Capital Per Executive | 1.6M |
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |